Discover the Innovation of ProGo® by Hofseth Biocare ASA
Unlocking the Potential of ProGo® for Health
Hofseth Biocare ASA (Oslo: HBC) has recently introduced a groundbreaking product known as ProGo®, which is considered the world’s first consumer health GLP-1 and GIP receptor agonist. This innovative ingredient is uniquely designed to provide comprehensive support for individuals looking to enhance their health. The whitepaper released by the company dives deep into how ProGo® functions at a biological level, especially its remarkable ability to protect lean muscle mass while optimizing weight loss benefits.
Understanding the Need for Muscle Mass Protection
To fully harness the advantages of GLP-1 therapy, it is critical to prioritize the preservation of lean muscle mass. This is vital not just for effective weight loss, but also for maintaining a healthy metabolism. Without addressing muscle mass, even the most efficient weight loss strategies may fall short. ProGo® emerges as a solution tailored to overcome these challenges, boasting a unique triple action mechanism that effectively meets these health needs.
Triple Action Mechanism of ProGo®
The innovative features of ProGo® can be attributed to its three-fold action. First, it serves as a highly absorbable protein that provides a complete amino acid profile essential for muscle building. Second, it offers antioxidant and anti-inflammatory properties that are crucial for the protection of muscle health. Lastly, ProGo® works to inhibit Myostatin and Activin A, two negative regulators of muscle mass. Through this multifaceted approach, ProGo® is positioned to support optimal health.
Why ProGo® Stands Out in the Market
ProGo® is not just another peptide supplement—it holds the unique designation of being both a GLP-1 receptor agonist and a targeted muscle protector. This dual-action mechanism is a significant advancement in the realm of nutritional supplements. As a high-quality, fully traceable product, ProGo® consists of hydrolyzed peptides and collagen that ensure a complete amino acid profile, including high concentrations of branched-chain amino acids (BCAAs), which are crucial for muscle formation and overall health.
Superior Bioavailability
One of ProGo®’s distinguishing features is its higher bioavailability compared to other peptides on the market. The smaller size of its peptides enables the body to digest and absorb them more efficiently, resulting in enhanced effectiveness. This factor plays a pivotal role in making ProGo® a remarkable addition to any health regime.
About Hofseth Biocare ASA
Founded on principles of sustainability and resource optimization, Hofseth Biocare ASA is a Norwegian company dedicated to improving both human and pet health. By transforming byproducts from the salmon industry into valuable health ingredients, HBC exemplifies innovation in nutrition. Their flagship products include Proteins like ProGo®, healthy salmon oil branded as OmeGo®, and CalGo® / NT-II® salmon bone powder designed for bone and joint health.
Scientific Backing and Future Innovations
The company prides itself on placing scientific validation at the forefront of its efforts. With a robust commitment to research, HBC has forged partnerships with various academic entities, leading to the identification of unique health benefits, such as enhancing iron metabolism and triggering the GLP-1 receptor to support weight management in overweight adults. The functionality of OmeGo® extends to immune health, while CalGo® / NT-II® is associated with bone and joint benefits that ambitiously target healthy aging and active lifestyles.
HBC has also secured numerous patents to protect its innovative discoveries. The company continues to push the boundaries of health science through its biotech sibling, HBC Immunology (HBCI), focusing on areas like prostate and ovarian cancer treatment. Their developments hold promise in creating steroid-sparing therapies for asthma, showcasing Hofseth Biocare ASA’s dedication to healthcare innovation.
For any inquiries, please reach out to:
James Berger, CCO at Hofseth BioCare ASA
Phone: +41 79 950 1034
E-mail: jb@hofsethbiocare.no
Frequently Asked Questions
What is ProGo®?
ProGo® is a bioactive peptide ingredient designed to support GLP-1 therapy while protecting lean muscle mass.
How does ProGo® protect muscle mass?
It inhibits Myostatin and Activin A, which are natural regulators that limit muscle growth.
What benefits does ProGo® offer over traditional protein supplements?
ProGo® has superior bioavailability and a unique combination of muscle support and metabolic enhancement.
How can I contact Hofseth Biocare ASA?
You can reach James Berger at +41 79 950 1034 or via email at jb@hofsethbiocare.no.
Is Hofseth Biocare ASA publicly listed?
Yes, it is listed on the Oslo Stock Exchange under the ticker HBC.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
